SCHEMBL6355304

SCHEMBL6355304

Cc1ccc(S(=O)(=O)NCCN(CCNS(=O)(=O)c2ccc(C)cc2)CCN(CCNS(=O)(=O)c2ccc(C)cc2)CCNS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.71
CA12 O43570 1/20 0.66
CA2 P00918 1/20 0.66
CA9 Q16790 1/20 0.66
ALOX15 P16050 1/20 0.64
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
SIGMAR1 Q99720 2/20 0.61
LMNA P02545 1/20 0.55
HPGD P15428 1/20 0.55
HTT P42858 1/20 0.55
TSHR P16473 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581466 1.00 ALDH1A1 (0.71) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL12691657 0.94 ALDH1A1 (0.63) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL12629240 0.92 ALDH1A1 (0.61) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL13955399 0.89 ALDH1A1 (0.58) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL14139848 0.87 ALDH1A1 (0.56) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL12629636 0.86 ALDH1A1 (0.71) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL6130639 0.86 CA12 (0.81) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL6354094 0.85 ALDH1A1 (0.66) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL5567042 0.85 ALDH1A1 (0.75) ALDH1A1CA12CA2CA9ALOX15
SCHEMBL565872 0.84 ALDH1A1 (0.60) ALDH1A1CA12CA2CA9ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084303-A1 Complexes and Ligands THE GENERAL HOSPITAL CORPORATION 2025-03-13 US disclosed
US-12134721-B2 Complexes and ligands THE GENERAL HOSPITAL CORPORATION (US) 2024-11-05 US disclosed
EP-4424686-A1 COMPLEXES AND LIGANDS The General Hospital Corporation (US) 2024-09-04 EP disclosed
EP-3870044-B1 COMPLEXES AND LIGANDS MASSACHUSETTS GEN HOSPITAL (US) 2024-04-10 EP disclosed
US-20220025254-A1 Complexes and Ligands THE GENERAL HOSPITAL CORPORATION 2022-01-27 US disclosed
EP-2423201-B1 Luminescent macrocyclic lanthanide complexes UNIV CALIFORNIA (US) 2017-10-04 EP disclosed
US-8729258-B2 Luminescent macrocyclic lanthanide complexes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-20 US disclosed
US-8729258-B2 Luminescent macrocyclic lanthanide complexes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-20 US disclosed
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-12-27 US disclosed
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-12-27 US disclosed
US-8173800-B2 Hydroxy-isophthalamide moieties; antibodies; high stability, luminescence; kits THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-08 US disclosed
US-8173800-B2 Hydroxy-isophthalamide moieties; antibodies; high stability, luminescence; kits THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-08 US disclosed
EP-2423201-A1 Luminescent macrocyclic lanthanide complexes The Regents of The University of California (US) 2012-02-29 EP disclosed
US-20080213917-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-04 US disclosed
WO-2008063721-A2 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213917-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES SSB, HACD3, CLTA ALDH1A1 4586/4885CA12 541/4885CA2 490/4885
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES SSB, HACD3, CLTA ALDH1A1 4586/4885CA12 541/4885CA2 490/4885
US-20250084303-A1 Complexes and Ligands BID, CLTB, NECTIN4 ALDH1A1 3131/4885CA12 335/4885CA2 2677/4885
US-20220025254-A1 Complexes and Ligands BID, CLTB, NECTIN4 ALDH1A1 3131/4885CA12 335/4885CA2 2677/4885
US-12134721-B2 Complexes and ligands BID, CLTB, NECTIN4 ALDH1A1 3131/4885CA12 335/4885CA2 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.